March 22, 2021
1 min watch
Save
VIDEO: MBCC’s debates on HER2 targeted therapies a ‘controversial area’
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Kelly K. Hunt, MD, FACS, FSSO, professor and chair of the department of breast surgical oncology at The University of Texas MD Anderson Cancer Center, discussed upcoming debates on targeted therapies at the 38th Annual Miami Breast Cancer Conference. Hunt said she was excited to participate in debates on best timing and options in emerging therapies for patients.
“I'm looking forward to the medical crossfire on HER2 targeted therapies, whether they should be utilized in the neoadjuvant or the adjuvant setting for patients with very early-stage breast cancer,” Hunt said.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Hunt reports serving on a medical board for Armada Health Care and Merck & Co.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.